Genetic Testing for Developmental Disabilities Low Among Children Enrolled in Medicaid
FRIDAY, June 27, 2025 -- Clinical implementation of genetic testing in children with neurodevelopmental disabilities in the Medicaid-enrolled population remains low, according to a study published online June 18 in Genetics in Medicine.
Tashalee R. Brown, M.D., Ph.D., from the University of California, Los Angeles, and colleagues examined clinical implementation of existing genetic testing medical guidelines for children with autism spectrum disorder (ASD) and/or intellectual disability (ID) among enrollees of Medicaid or Children’s Health Insurance Program plans. Analysis included data from 241,060 children aged 7 to 17 years.
The researchers found that the frequency of genetic testing was low across diagnoses, with ASD + ID showing the highest frequency of 25.94 percent. Children with ASD + ID had the highest odds of genetic testing (adjusted odds ratio, 29.43) versus a random sample of children without ASD or ID. In 2013, cytogenetics and Fragile X testing were the predominant testing types used, followed by increasing use of chromosomal microarray analysis and gene panels in 2014 to 2016.
"Genetic testing can offer valuable insights for diagnosis and care planning," Brown said in a statement. "But our findings show a major gap between what’s recommended and what’s actually happening in clinical practice among children who receive health insurance through Medicaid."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.